Fit-for-purpose biomarker method validation in anticancer drug development.
AffiliationClinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, England, United Kingdom.
MetadataShow full item record
AbstractThe introduction of new anticancer drugs into the clinic is often hampered by a lack of qualified biomarkers. Method validation is indispensable to successful biomarker qualification and is also a regulatory requirement. Recently, the fit-for-purpose approach has been developed to promote flexible yet rigorous biomarker method validation, although its full implications are often overlooked. This review aims to clarify many of the scientific and regulatory issues surrounding biomarker method validation and the analysis of samples collected from clinical trial subjects. It also strives to provide clear guidance on validation strategies for each of the five categories that define the majority of biomarker assays, citing specific examples.
CitationFit-for-purpose biomarker method validation in anticancer drug development. 2010: Drug Discov Today
JournalDrug Discovery Today
- Biomarker method validation in anticancer drug development.
- Authors: Cummings J, Ward TH, Greystoke A, Ranson M, Dive C
- Issue date: 2008 Feb
- Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
- Authors: Lee JW, Figeys D, Vasilescu J
- Issue date: 2007
- Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.
- Authors: Cummings J, Raynaud F, Jones L, Sugar R, Dive C
- Issue date: 2010 Oct 26
- The cross-validated adaptive signature design.
- Authors: Freidlin B, Jiang W, Simon R
- Issue date: 2010 Jan 15
- Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis.
- Authors: Lee JW, Hall M
- Issue date: 2009 May 1